WO2017071173A1 - Agent thérapeutique antitumoral modifié par protéine de fusion il-12/cd62l, son procédé de préparation et son utilisation - Google Patents
Agent thérapeutique antitumoral modifié par protéine de fusion il-12/cd62l, son procédé de préparation et son utilisation Download PDFInfo
- Publication number
- WO2017071173A1 WO2017071173A1 PCT/CN2016/080420 CN2016080420W WO2017071173A1 WO 2017071173 A1 WO2017071173 A1 WO 2017071173A1 CN 2016080420 W CN2016080420 W CN 2016080420W WO 2017071173 A1 WO2017071173 A1 WO 2017071173A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- protein
- cells
- cd62l
- fusion protein
- tumor
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 88
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 88
- 206010028980 Neoplasm Diseases 0.000 title abstract description 77
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 239000003814 drug Substances 0.000 title description 5
- 229940124597 therapeutic agent Drugs 0.000 title description 3
- 108010065805 Interleukin-12 Proteins 0.000 claims abstract description 120
- 102000013462 Interleukin-12 Human genes 0.000 claims abstract description 118
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims abstract description 109
- 102100033467 L-selectin Human genes 0.000 claims abstract description 105
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 61
- 230000004927 fusion Effects 0.000 claims abstract description 11
- 210000004027 cell Anatomy 0.000 claims description 89
- 235000018102 proteins Nutrition 0.000 claims description 43
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 38
- 239000013598 vector Substances 0.000 claims description 38
- 238000000034 method Methods 0.000 claims description 32
- 210000002865 immune cell Anatomy 0.000 claims description 28
- 230000014509 gene expression Effects 0.000 claims description 27
- 108091033319 polynucleotide Proteins 0.000 claims description 20
- 102000040430 polynucleotide Human genes 0.000 claims description 20
- 239000002157 polynucleotide Substances 0.000 claims description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 235000004252 protein component Nutrition 0.000 claims description 4
- 239000013603 viral vector Substances 0.000 claims description 4
- 241000710772 Yellow fever virus Species 0.000 claims description 2
- 229940051021 yellow-fever virus Drugs 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 abstract description 107
- 230000000259 anti-tumor effect Effects 0.000 abstract description 35
- 239000000427 antigen Substances 0.000 abstract description 27
- 108091007433 antigens Proteins 0.000 abstract description 27
- 102000036639 antigens Human genes 0.000 abstract description 27
- 238000003776 cleavage reaction Methods 0.000 abstract description 23
- 230000007017 scission Effects 0.000 abstract description 23
- 230000001419 dependent effect Effects 0.000 abstract description 9
- 210000000170 cell membrane Anatomy 0.000 abstract description 8
- 241000713666 Lentivirus Species 0.000 abstract description 5
- 230000004913 activation Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 description 25
- 108091008874 T cell receptors Proteins 0.000 description 22
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 21
- 239000012528 membrane Substances 0.000 description 21
- 210000004881 tumor cell Anatomy 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 17
- 101000578784 Homo sapiens Melanoma antigen recognized by T-cells 1 Proteins 0.000 description 15
- 102100028389 Melanoma antigen recognized by T-cells 1 Human genes 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 239000006228 supernatant Substances 0.000 description 14
- 108020004414 DNA Proteins 0.000 description 13
- 102000004196 processed proteins & peptides Human genes 0.000 description 13
- 239000013604 expression vector Substances 0.000 description 12
- 238000000338 in vitro Methods 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 231100000331 toxic Toxicity 0.000 description 12
- 230000002588 toxic effect Effects 0.000 description 12
- 229920001184 polypeptide Polymers 0.000 description 11
- 238000010361 transduction Methods 0.000 description 11
- 238000000684 flow cytometry Methods 0.000 description 10
- 230000026683 transduction Effects 0.000 description 10
- 101001023379 Homo sapiens Lysosome-associated membrane glycoprotein 1 Proteins 0.000 description 8
- 102100035133 Lysosome-associated membrane glycoprotein 1 Human genes 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 238000007796 conventional method Methods 0.000 description 8
- 238000010276 construction Methods 0.000 description 7
- 230000028327 secretion Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 238000008157 ELISA kit Methods 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 238000003501 co-culture Methods 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108010092694 L-Selectin Proteins 0.000 description 5
- 102000016551 L-selectin Human genes 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 241000700605 Viruses Species 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 239000002773 nucleotide Substances 0.000 description 5
- 125000003729 nucleotide group Chemical group 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 230000009885 systemic effect Effects 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 4
- 108050005493 CD3 protein, epsilon/gamma/delta subunit Proteins 0.000 description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 4
- 108010002350 Interleukin-2 Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 4
- 108010004469 allophycocyanin Proteins 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 230000001588 bifunctional effect Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 210000003527 eukaryotic cell Anatomy 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 230000036039 immunity Effects 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- NEHKZPHIKKEMAZ-ZFVKSOIMSA-N (2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s,3s)-2-[[2-[[(2s)-2-[[(2s)-2-azaniumylpropanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylb Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O NEHKZPHIKKEMAZ-ZFVKSOIMSA-N 0.000 description 3
- 102000043279 ADAM17 Human genes 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 3
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 3
- 108010010995 MART-1 Antigen Proteins 0.000 description 3
- 102000016200 MART-1 Antigen Human genes 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000005975 antitumor immune response Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000005090 green fluorescent protein Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 238000010188 recombinant method Methods 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 2
- 108091007505 ADAM17 Proteins 0.000 description 2
- 108700031361 Brachyury Proteins 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091033380 Coding strand Proteins 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108090001126 Furin Proteins 0.000 description 2
- 102000004961 Furin Human genes 0.000 description 2
- 108700023863 Gene Components Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 238000012404 In vitro experiment Methods 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 238000012408 PCR amplification Methods 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000002798 bone marrow cell Anatomy 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000022534 cell killing Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004520 electroporation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 238000012215 gene cloning Methods 0.000 description 2
- 238000012239 gene modification Methods 0.000 description 2
- 238000007429 general method Methods 0.000 description 2
- 102000051200 human SELL Human genes 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000007917 intracranial administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000007270 liver cancer Diseases 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 210000001165 lymph node Anatomy 0.000 description 2
- 210000003712 lysosome Anatomy 0.000 description 2
- 230000001868 lysosomic effect Effects 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000002085 persistent effect Effects 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000004989 spleen cell Anatomy 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000005199 ultracentrifugation Methods 0.000 description 2
- 101150056050 ADAM17 gene Proteins 0.000 description 1
- 206010063746 Accidental death Diseases 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710091045 Envelope protein Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 101710088172 HTH-type transcriptional regulator RipA Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000924345 Homo sapiens Ankyrin repeat domain-containing protein 36B Proteins 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710118186 Neomycin resistance protein Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- KHGNFPUMBJSZSM-UHFFFAOYSA-N Perforine Natural products COC1=C2CCC(O)C(CCC(C)(C)O)(OC)C2=NC2=C1C=CO2 KHGNFPUMBJSZSM-UHFFFAOYSA-N 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 101710188315 Protein X Proteins 0.000 description 1
- 239000012979 RPMI medium Substances 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- 230000033540 T cell apoptotic process Effects 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000006023 anti-tumor response Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000001159 caudate nucleus Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 229940029030 dendritic cell vaccine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 102000004419 dihydrofolate reductase Human genes 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000014726 immortalization of host cell Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000010297 mechanical methods and process Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 210000003632 microfilament Anatomy 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229930192851 perforin Natural products 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- -1 polypropylene Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010814 radioimmunoprecipitation assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 238000003151 transfection method Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/867—Retroviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the invention relates to the field of medicine, in particular to a tumor therapeutic agent modified by an IL-12/CD62L fusion protein, a preparation method thereof and use thereof.
- the present invention provides a class of IL-12/CD62L gene-modified T cells with enhanced anti-tumor effects.
- IL-12 is a very important immune stimulating factor.
- IL-12 is a heterodimeric cytokine linked by a covalent bond, consisting of the p35 and p40 subunits, secreted by activated immune cells in vivo.
- IL-12 is an important cellular immune regulatory factor that acts through NK cells and CTLs in immunity against infection and malignancy.
- IL-12 has a significant antitumor effect, it is extremely limited due to systemic systemic administration which causes systemic toxic side effects.
- Prior to the present invention the clinical application of IL-12 was greatly limited in clinical application due to the systemic toxic side effects induced by it and the accidental death of two patients caused by systemic administration in early clinical trials.
- the present inventors have attempted to maximize the antitumor effect by genetically modifying anti-tumor T cells to continuously secrete IL-12, but for unknown reasons (a possible cause is the side effects of IL-12) T cells that have been genetically modified by sustained secretion of the IL-12 gene are not efficiently amplified in vitro and cause a large number of T cell apoptosis.
- the present inventors have also succeeded in the effective amplification of T cells in vitro by TCR activation of a gene modification scheme that specifically regulates the expression of IL-12, and have also achieved certain antitumor effects, but at the same time, IL exists.
- the toxic side effects caused by -12 out of regulation cannot be effectively applied to clinical applications.
- the object of the present invention is to provide a tumor therapeutic drug with high efficiency and low toxic and side effects, and a preparation method and application thereof.
- a fusion protein comprising the following elements fused together:
- signal peptide is operably linked to the fusion element consisting of (ii), (iii) and (iv);
- the first protein element is an IL-12 protein element; the second protein element is a protein element of CD62L.
- operably linked means that the signal peptide can direct expression or transmembrane transfer (localization) of the fusion element.
- the fusion protein has a structure selected from the group consisting of:
- A is an IL-12 protein element
- B is a CD62L protein element
- C is an optional linker element
- D is an optional signal peptide signal peptide and/or leader peptide sequence
- the linker peptide element comprises a linker peptide having the sequence set forth in SEQ ID NO.: 7.
- the IL-12 protein is derived from a human or a non-human mammal.
- the IL-12 protein comprises wild type and mutant form.
- the IL-12 protein comprises a full length, mature form of IL-12, or an active fragment thereof.
- the first protein element comprises one or two subunits of an IL-12 protein.
- the subunit of the IL-12 protein is selected from the group consisting of the P40 and P35 subunits.
- the first protein element comprises the IL-12 protein P40 and P35 subunits joined together.
- the P40 and P35 subunits are "head-to-head”, “head-to-tail”, and “tail-tail”.
- a linker is present or absent between the P40 and P35 subunits.
- the linker is a flexible linker of 4-20 amino acids, more preferably, the linker is GGGGGGS (G 6 S) (SEQ ID NO.:8)
- sequence of the IL12 protein element is set forth in SEQ ID NO.: 4.
- the CD62L protein element has a cleavage site for K283-S284.
- the CD62L protein is derived from a human or non-human mammal.
- the CD62L protein comprises wild type and mutant form.
- the CD62L protein comprises a full length, mature form of CD62L, or an active fragment thereof.
- sequence of the CD62L protein element is set forth in SEQ ID NO.: 6.
- the peptide linker is 0-15 amino acids in length, preferably 1-10 amino acids.
- the fusion protein further comprises a signal peptide element D.
- the first protein element in the fusion protein, is a single-stranded IL-12, and in the single-stranded IL-12, a linker peptide G 6 S is provided in the P40 subunit and the P35 subunit. (SEQ ID NO.: 7).
- the fusion protein is in single-stranded IL-12 (first protein element) and CD62L (second protein)
- a linker peptide is provided between the elements), preferably a peptide 218 (SEQ ID NO.: 8).
- amino acid sequence of the fusion protein is shown in SEQ ID NO.: 2.
- the fusion protein has the following characteristics:
- the fusion protein is cleaved by the ADAM17 protein to release IL-12;
- the fusion protein comprises two subunits of IL-12, namely the P40 and P35 subunits, and is joined by GGGGGGS (G6S).
- the fusion protein is a monomer, or a dimer.
- an isolated polynucleotide is provided, the polynucleotide encoding the fusion protein of the first aspect.
- sequence of the polynucleotide is set forth in SEQ ID NO.: 1.
- a vector comprising the polynucleotide of the second aspect of the invention is provided.
- the vector comprises a plasmid, a viral vector.
- the viral vector comprises a lentiviral vector, an adenoviral vector, and a yellow fever virus vector.
- the vector comprises an expression vector.
- a host cell comprising the vector of the third aspect of the invention or the polynucleotide of the second aspect integrated in the genome.
- the host cell comprises a prokaryotic cell and a eukaryotic cell.
- the host cell comprises a mammalian cell.
- the host cell comprises an immune cell, preferably a T cell,
- a method of producing the protein of the first aspect comprising the steps of:
- composition comprising:
- the fusion protein of the first aspect and
- a pharmaceutically acceptable carrier is selected from:
- an immune cell carrying or present on the cell surface thereof) the fusion protein of the first aspect.
- the immune cells of at least 10 3 (preferably 103 to 109, more preferably preferably 104-108 th) the cell population of immune cells.
- At least a portion or all of said fusion protein is located on the cell membrane of said immune cell, and said first protein element, i.e., the IL-12 protein element, is located extracellularly.
- the immune cells comprise T cells.
- the T cell surface carries a MART-1 TCR.
- composition comprising:
- a pharmaceutically acceptable carrier is selected from:
- the pharmaceutical composition is in a liquid state.
- the pharmaceutical composition contains 1 x 10 3 - 1 x 10 7 of said immune cells/ml.
- the use of the fusion protein of the first aspect and/or the immune cell of the seventh aspect, for the preparation of a medicament for treating a tumor is provided.
- the tumor comprises: a brain tumor, a colorectal cancer tumor, a lung cancer tumor, a liver cancer tumor, a breast cancer tumor, a gastric cancer tumor, and a pancreatic cancer tumor.
- a method of treating a tumor comprising the step of administering the fusion protein of the first aspect and/or the immune cell of the seventh aspect to a subject in need thereof.
- the fusion protein is administered as a monomer and/or a dimer.
- the object is a human.
- Figure 1 shows membrane surface cleavage and release induced by antigen-specific activation by CD62L/L-selectin.
- FIG. 1A and FIG. 1B show schematic diagrams of the molecular mechanism of membrane molecule CD62L cleavage and release.
- CD62L on the surface of T cells undergoes directed aggregation of microfilaments (actin, etc.) under the action of specific activators such as antigens, resulting in specific cleavage membrane molecules of the cleavage enzyme (Adam17, etc.) on the surface of the cell membrane.
- specific activators such as antigens
- FIG. 1C shows tumor antigen-induced membrane molecule-specific cleavage and release.
- Tumor cell 526 is a related antigen MART-1 expressing MHC I A2 molecule, which is a positive target cell; 938 tumor cell does not express MHC A2 molecule, and is a negative control cell.
- PBMC was activated by anti-CD3/CD28 magnetic beads for 24 hours, T cells were transduced with lentiviral engineering supernatant expressing anti-tumor MART-1 TCR; 14 days later, T cells were associated with MART-1 antigen-expressing tumor cells 938 and 526 Co-culture. As shown in the figure, co-cultured T cells were tested for molecular CD45RO and CD62L on the surface of the membrane by flow cytometry.
- the T cells of each group were sorted into CD8 cell subsets (column 1 and column 3) by FlowJo software analysis. And CD8/MART-1 cell subsets (column 2 and column 4).
- the time points noted on the right indicate the time of collection and analysis of cells after co-culture, for a total of 4 time points: 1 h, 2 h, 4 h and 6 h.
- the antibodies used in flow cytometry were CD62L FITC, CD45RO APC, MART-1PE and CD8 PercP.
- Figure 2 shows that the cleavage and release of CD62L is dependent on tumor antigen stimulation.
- PBMCs were transactivated by anti-CD3/CD28 magnetic beads for 24 hours, and T cells were transduced with lentiviral engineering supernatant expressing anti-tumor MART-1 TCR; 14 days later, T cells were associated with MART-1 antigen-expressing tumor cells 938 and 526 was co-cultured for 4 h.
- the co-cultured T cells were detected by flow cytometry on the surface of the membrane CD45RO and CD62L, and analyzed by FlowJo software, each group of T cells were sorted into CD8, CD8/MART- 1 cell subpopulation.
- CD62L levels in free CD62L and co-cultured cells in the supernatant were detected by ELISA kit.
- the amount of CD62L in the supernatant of the T+526 group was set to 100%, and the other groups calculated the percentage of the CD62L content by comparison.
- Figure 3 shows that the cleavage of CD62L is a prerequisite for CD107a expression.
- T cells were transduced by anti-tumor MART-1 TCR, co-cultured and analyzed and organized by FACS (as described above).
- FACS The antibodies used for the assay were as follows, CD107a FITC, MART-1PE, CD8 PercP5.5, CD45RO PE Cy-7, CD62L APC, CD3APC Cy-7.
- CD107a in each T cell subset is indicated by the arrow.
- the lower panel EM represents the effector memory cells of CD62L-CD45RO+; CM represents the central memory cells of CD62L+CD45RO+.
- Figure 4 shows the specific cleavage and release of IL-12 in the fusion protein CD62L/IL-12 induced by tumor antigen.
- CD62L after CD62L is activated by tumor antigen, CD62L undergoes tumor antigen-induced cleavage and release.
- the mechanism diagram shows how IL-12 in CD62L/IL-12 fusion protein is cleaved and released, ie, fusion protein IL-12 occurs. Partial release. According to this effector mechanism, the release of biologically active IL-12 can increase the recognition of tumor cells by anti-tumor T cells, thereby maximizing the anti-tumor effect.
- TCR, CD107a, Perforin, Granzyme, CD62L and IL-12 are shown in the figure.
- Figure 5 shows the construction of a lentiviral vector expressing a CD62L/IL-12 fusion protein and its expression in human T cells.
- Figure 6 shows that co-culture of lentiviral vector hscIL-12/CD62L transduced T cells with tumors enhances IFNy expression and tumor antigen-dependent release of IL-12.
- Figure 7 shows that lentiviral vector hscIL-12/CD62L-transduced murine T cell-mediated cell transfusion therapy significantly prolongs survival in tumor-bearing mice.
- Figure 8 shows that the lentiviral vector hscIL-12/CD62L transduced T cells can effectively avoid the toxic side effects of in vitro T cell expansion caused by persistent secretion of IL-12.
- the fusion protein of the invention is an IL-12/CD62L fusion protein.
- IL-12/CD62L fusion protein when expressed in T cells, it is effectively displayed on the surface of T cells.
- the IL-12/CD62L fusion protein has little effect on the viability of T cells, and the anti-tumor T cells carrying the fusion protein of the present invention can be tumor antigen-dependent when approaching tumor cells.
- the induced specific cleavage of CD62L is activated to release IL-12 at a site near the tumor cells, ie, release of IL-12 on the surface of the cell membrane that activates the tumor antigen.
- IL-12 is activated to release IL-12 at a site near the tumor cells, ie, release of IL-12 on the surface of the cell membrane that activates the tumor antigen.
- maximization of anti-tumor immunity effect can be achieved very effectively, and IL- is extremely significantly reduced. 12 toxic side effects.
- the present invention has been completed on this basis.
- the present inventors adopted a protocol for connecting IL-12 by expressing a cell membrane, and in view of the specific release of tumor antigen reactivity of IL-12, the present invention innovatively employs IL-12 and CD62L.
- IL-12 and CD62L A strategy of fusion that regulates the specific release of tumor immunity by IL-12 by cleavage of CD62L tumor antigen reactivity.
- IL-12/CD62L lentiviral gene-modified T cells are used to enhance the anti-tumor effect, and the tumor antigen-dependent cleavage and release of CD62L is demonstrated by in vitro experiments, further confirming lentiviral-mediated fusion.
- the protein IL-12/CD62L can not only effectively modify the anti-tumor T cell expression fusion protein, but also can release the IL-12 on the membrane surface by CD62L cleavage.
- T cell/tumor cell co-culture experiments demonstrated that IL-12/CD62L lentiviral gene-modified anti-tumor T cells can significantly increase the intensity of the immune response, which is shown to significantly enhance the secretion level of IFN ⁇ .
- head refers to the N-terminus of a polypeptide or fragment thereof, particularly the N-terminus of a wild-type polypeptide or fragment thereof.
- tail refers to the C-terminus of a polypeptide or fragment thereof, particularly the C-terminus of a wild-type polypeptide or fragment thereof.
- containing includes “including”, “consisting essentially of”, “consisting essentially of”, and “consisting of”;
- the subordinate concepts of “consisting of”, “consisting essentially of” and “consisting of” are “contained,” “having,” or “including.”
- CD62L is widely expressed on the surface of T cells and is an important immunoregulatory factor. It can regulate the migration of T cells to the lymph nodes of the whole body and is an important T cell homing factor.
- CD62L+T cell migrates to the lymph node and is exposed to the tumor antigen, CD62L can be tested for tumor antigen reactivity by ADAM17 on the peptide K283-S284 at the transmembrane region.
- CD62L cleavage has the specificity of a tumor antigen reaction accompanied by CD107a (the molecule is a molecular protein on the lysosome, which is normally present in the cell)
- the molecule migrates to the cell surface accompanied by degranulation of T cells; therefore, membrane surface detection of this molecule is an important indicator of membrane migration of T cell killing.
- IL-12 is a very important immune stimulating factor.
- IL-12 is a heterodimeric cytokine linked by a covalent bond, consisting of the p35 and p40 subunits, secreted by activated immune cells in vivo.
- the IL-12 may be derived from a human or non-human mammal, and may be a full-length, mature form of IL-12, or an active fragment thereof.
- the IL-12 (or IL-12 protein element) can be a single subunit or multiple subunits.
- the first protein element may comprise one or more (e.g., two) subunits of an IL-12 protein.
- the first protein element comprises the IL-12 protein P40 and P35 subunits joined together.
- the manner of connecting the P40 and P35 subunits is not particularly limited, and includes "head-to-head”, “head-to-tail”, “tail-head”, and “tail-tail”, wherein “ “Head” refers to the N-terminus of a polypeptide, and “tail” refers to the C-terminus of a polypeptide.
- a linker may or may not be present between the P40 and P35 subunits.
- the linker is a flexible linker of 4-20 amino acids, more preferably, the linker is GGGGGGS (G 6 S) (SEQ ID NO.:8)
- the bifunctional fusion proteins of the invention may optionally contain a peptide linker.
- the size and complexity of the peptide linker may affect the activity of the protein.
- the peptide linker should be of sufficient length and flexibility to ensure that the two proteins attached have sufficient freedom in space to perform their function. At the same time, the effect of the formation of an alpha helix or a beta sheet in the peptide linker on the stability of the fusion protein is avoided.
- the length of the linker peptide is generally from 0 to 15 amino acids, preferably from 1 to 15 amino acids.
- linker peptides include, but are not limited to, the linker peptide set forth in SEQ ID NO.: 7 or 8.
- the fusion protein of the present invention may also contain other elements including, but not limited to, signal peptides, leader peptides and the like.
- the fusion protein contains a signal peptide.
- Representative examples include (but are not limited to): human sources Signal peptide of the IL-12P40 subunit.
- the fusion protein is an isolated protein that is not associated with other proteins, polypeptides or molecules and is a product expressed by recombinant host cells, or isolated or purified.
- bifunctional fusion protein in the present invention, "recombinant bifunctional fusion protein", "protein of the present invention”, “fusion protein of the present invention”, “bifunctional fusion protein”, “IL-12-CD62L fusion protein”, “IL-12/CD62L fusion” “protein” is used interchangeably and refers to a structure having the structure of Formula Ia, or the structure described in IIa, ie, a fusion protein comprising a protein element comprising an IL-12 protein element, CD62L, and a linker element.
- a representative example is IL12-CD62L.
- the protein of the invention may be a monomer or a multimer (e.g., a dimer) formed from a monomer.
- the term also encompasses active fragments and derivatives of fusion proteins.
- isolated means that the substance is separated from its original environment (if it is a natural substance, the original environment is the natural environment).
- the polynucleotides and polypeptides in the natural state in living cells are not isolated and purified, but the same polynucleotide or polypeptide is isolated and purified, as separated from other substances present in the natural state.
- isolated recombinant fusion protein means that the recombinant fusion protein is substantially free of other proteins, lipids, carbohydrates or other materials with which it is naturally associated.
- One skilled in the art can purify recombinant fusion proteins using standard protein purification techniques. Substantially pure proteins produce a single major band on a non-reducing polyacrylamide gel.
- the polynucleotide of the present invention may be in the form of DNA or RNA.
- DNA forms include cDNA, genomic DNA or synthetic DNA.
- DNA can be single-stranded or double-stranded.
- the DNA can be a coding strand or a non-coding strand.
- the present invention also relates to variants of the above polynucleotides which encode protein fragments, analogs and derivatives having the same amino acid sequence as the present invention.
- Variants of this polynucleotide may be naturally occurring allelic variants or non-naturally occurring variants. These nucleotide variants include substitution variants, deletion variants, and insertion variants.
- an allelic variant is an alternative form of a polynucleotide that may be a substitution, deletion or insertion of one or more nucleotides, but does not substantially alter the function of the polypeptide encoded thereby.
- the term "primer” refers to a generic term for a oligodeoxynucleotide that, in pairing with a template, can be used to synthesize a DNA strand complementary to a template under the action of a DNA polymerase.
- the primer may be native RNA, DNA, or any form of natural nucleotide.
- the primer may even be a non-natural nucleotide such as LNA or ZNA.
- the primer is “substantially” (or “substantially") complementary to a particular sequence on a strand on the template.
- the primer must be sufficiently complementary to a strand on the template to initiate extension, but the sequence of the primer need not be fully complementary to the sequence of the template.
- a sequence that is not complementary to the template is added to the 5' end of a primer complementary to the template at the 3' end, such primers are still substantially complementary to the template.
- the non-fully complementary primers can also form a primer-template complex with the template for amplification.
- the fusion protein of the present invention can conveniently prepare by various known methods. These methods are, for example but not limited to, recombinant DNA methods, artificial synthesis, and the like.
- the full-length nucleotide sequence of the element of the fusion protein of the present invention (such as IL12 or CD62L) or a fragment thereof can usually be amplified by PCR. Obtained by law, recombinant method or synthetic method.
- primers can be designed according to published nucleotide sequences, particularly open reading frame sequences, and used as commercially available cDNA libraries or cDNA libraries prepared by conventional methods known to those skilled in the art.
- the template is amplified to obtain the relevant sequence. When the sequence is long, it is often necessary to perform two or more PCR amplifications, and then the amplified fragments are spliced together in the correct order.
- the recombinant sequence can be used to obtain the relevant sequences in large quantities. This is usually done by cloning it into a vector, transferring it to a cell, and then isolating the relevant sequence from the proliferated host cell by conventional methods.
- synthetic sequences can be used to synthesize related sequences, especially when the fragment length is short.
- a long sequence of fragments can be obtained by first synthesizing a plurality of small fragments and then performing the ligation.
- a method of amplifying DNA/RNA using PCR technology is preferably used to obtain the gene of the present invention.
- the primers for PCR can be appropriately selected according to the sequence information of the present invention disclosed herein, and can be synthesized by a conventional method.
- the amplified DNA/RNA fragment can be isolated and purified by conventional methods such as by gel electrophoresis.
- the invention also relates to vectors comprising the polynucleotides of the invention, as well as host cells genetically engineered using the vector or fusion protein coding sequences of the invention, and methods of producing the proteins of the invention by recombinant techniques.
- polynucleotide sequences of the present invention can be utilized to express or produce recombinant proteins by conventional recombinant DNA techniques. Generally there are the following steps:
- Methods well known to those skilled in the art can be used to construct expression vectors containing the DNA sequences of the proteins of the invention and suitable transcription/translation control signals. These methods include in vitro recombinant DNA techniques, DNA synthesis techniques, in vivo recombinant techniques, and the like.
- the DNA sequence can be operably linked to an appropriate promoter in an expression vector to direct mRNA synthesis.
- the expression vector also includes a ribosome binding site for translation initiation and a transcription terminator.
- the expression vector preferably comprises one or more selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase for eukaryotic cell culture, neomycin resistance, and green Fluorescent protein (GFP), or tetracycline or ampicillin resistance for E. coli.
- selectable marker genes to provide phenotypic traits for selection of transformed host cells, such as dihydrofolate reductase for eukaryotic cell culture, neomycin resistance, and green Fluorescent protein (GFP), or tetracycline or ampicillin resistance for E. coli.
- Vectors comprising the appropriate DNA sequences described above, as well as appropriate promoters or control sequences, can be used to transform appropriate host cells to enable expression of the protein.
- the host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell.
- a prokaryotic cell such as a bacterial cell
- a lower eukaryotic cell such as a yeast cell
- a higher eukaryotic cell such as a mammalian cell.
- Representative examples are: Escherichia coli, bacterial cells of the genus Streptomyces; fungal cells such as yeast; plant cells; insect cells of Drosophila S2 or Sf9; animal cells of CHO, COS, or 293 cells, and the like.
- a particularly preferred cell is a cell of a human and a non-human mammal, especially an immune cell, including T cells, NK cells.
- Transformation of host cells with recombinant DNA can be carried out using conventional techniques well known to those skilled in the art.
- the host is a prokaryote such as E. coli
- competent cells capable of absorbing DNA can be harvested after the exponential growth phase and treated by the CaCl 2 method, and the procedures used are well known in the art.
- Another method is to use MgCl 2 .
- Conversion can also be carried out by electroporation if desired.
- the host is a eukaryote, the following DNA transfection methods can be used: calcium phosphate coprecipitation, conventional mechanical methods such as microinjection, electroporation, liposome packaging, and the like.
- the obtained transformant can be cultured by a conventional method to express the polypeptide encoded by the gene of the present invention.
- the medium used in the culture may be selected from various conventional media depending on the host cell used.
- the cultivation is carried out under conditions suitable for the growth of the host cell.
- the selected promoter is induced by a suitable method (such as temperature conversion or chemical induction) and the cells are cultured for a further period of time.
- the protein in the above method can be expressed intracellularly, or on the cell membrane, or secreted outside the cell. If desired, the protein can be isolated and purified by various separation methods using its physical, chemical, and other properties. These methods are well known to those skilled in the art. Examples of such methods include, but are not limited to, conventional renaturation treatment, treatment with a protein precipitant (salting method), centrifugation, osmotic sterilizing, super treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption layer Analysis, ion exchange chromatography, high performance liquid chromatography (HPLC) and various other liquid chromatography techniques and combinations of these methods.
- conventional renaturation treatment treatment with a protein precipitant (salting method), centrifugation, osmotic sterilizing, super treatment, ultracentrifugation, molecular sieve chromatography (gel filtration), adsorption layer Analysis, ion exchange chromatography, high performance liquid chromatography (HPLC) and
- the present invention also provides an immune cell (abbreviated as "the immune cell of the present invention”) expressing the fusion protein of the present invention, which carries the fusion protein on the cell surface.
- the immune cell of the present invention expresses the fusion protein of the present invention, which carries the fusion protein on the cell surface.
- the fusion protein is located on the cell membrane of the immune cell, and the first protein element, i.e., the IL-12 protein element, is located extracellularly.
- a preferred class of immune cells includes human T cells.
- said T cell surface carries a MART-1 TCR.
- a lentiviral expression system gene-modified T cell which expresses an anti-tumor TCR (T-cell receptor) and simultaneously expresses CD62L, hscIL-12 (human single-chain IL-12) And hscIL-12/CD62L fusion protein.
- the invention also provides a composition
- a composition comprising (a) an effective amount of a fusion protein of the invention and/or an effective amount of an immune cell of the invention, and a pharmaceutically acceptable carrier.
- the fusion proteins of the invention may be formulated in a non-toxic, inert, and pharmaceutically acceptable aqueous carrier medium wherein the pH is usually from about 5 to about 8, preferably from about 6 to about 8.
- the term "effective amount” or “effective amount” refers to an amount that is functional or active to a human and/or animal and that is acceptable to humans and/or animals, such as from 0.001 to 99% by weight; preferably 0.01-95 wt%; more preferably, 0.1-90 wt%.
- an effective amount or “effective amount” means 1 x 10 3 - 1 x 10 7 of said immune cells/ml.
- a "pharmaceutically acceptable” ingredient is one that is suitable for use in humans and/or mammals without excessive adverse side effects (eg, toxicity, irritation, and allergies), ie, having a reasonable benefit/risk ratio.
- pharmaceutically acceptable carrier refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
- compositions of the present invention comprise a safe and effective amount of a fusion protein of the invention and a pharmaceutically acceptable carrier.
- Such carriers include, but are not limited to, saline, buffer, dextrose, water, glycerol, ethanol, and combinations thereof.
- the pharmaceutical preparation should be matched to the mode of administration, and the pharmaceutical composition of the present invention can be prepared into an injection form, for example, by a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants.
- the pharmaceutical composition is preferably manufactured under sterile conditions.
- the amount of active ingredient administered is a therapeutically effective amount.
- the pharmaceutical preparation of the present invention can also be formulated into a sustained release preparation.
- the effective amount of the fusion protein of the present invention may vary depending on the mode of administration and the severity of the disease to be treated and the like. The selection of a preferred effective amount can be determined by one of ordinary skill in the art based on various factors (e.g., by clinical trials). The factors include, but are not limited to, pharmacokinetic parameters of the fusion protein of the invention such as bioavailability, metabolism, half-life, etc.; severity of the disease to be treated by the patient, body weight of the patient, immune status of the patient, administration Ways, etc.
- pharmacokinetic parameters of the fusion protein of the invention such as bioavailability, metabolism, half-life, etc.
- severity of the disease to be treated by the patient body weight of the patient, immune status of the patient, administration Ways, etc.
- a satisfactory effect can be obtained.
- several separate doses may be administered per day, or the dose may be proportionally reduced, as is critical to the condition of the treatment.
- the fusion proteins of the invention are particularly suitable for use in the treatment of diseases such as tumors.
- Representative tumors include, but are not limited to, colorectal cancer tumors, lung cancer tumors, liver cancer tumors, breast cancer tumors, gastric cancer tumors, and pancreatic cancer tumors.
- the fusion protein of the present invention is not significantly toxic to T cells
- the fusion protein of the present invention effectively inhibits the immune microenvironment of T cell-tumor tissue by locally and fixedly and periodically releasing IL-12 when T cells attack tumors, thereby inhibiting tumors very effectively and significantly reducing toxic side effect.
- the primers and DNA sequences used were all synthesized by Invitrogen.
- FIG. 5 is an engineering vector pLenti-MSCV containing a gene of interest, which is a promoter which is optimized for transduction of T cells by using MSCV as a promoter.
- the envelope protein particle pMD2.G contains VSV-G; gag/pol helper plasmid; and pRev plasmid system.
- the plasmids pRRLSIN.cPPT.MSCV/GFP and 293FT cells used were commercially available, and the reagents used were also commercially available.
- Tumor cells 938 and 526 are conventional melanoma cell lines (supplied by Dr. Rosenberg of the National Cancer Institute) and subcultured in vitro with 10% FCS RPMI medium and 0.25% pancreas every 2-3 days. Enzyme subculture. Both tumors express MART-1 antigen, of which 938 is MHC I A2-(negative) and 526 is MHC I A2+ (positive), and the genetically modified anti-tumor MART-1 T cells recognize only A2+ cell line, ie 526 cells.
- PBMC peripheral blood cells were derived from healthy human peripheral blood, and T cells were stimulated for growth with CD3/CD28 magnetic beads or CD3 antibody for 1 day, and cultured in IL-2 (100 IU/ml) X-VIVO medium. After recombinant lentivirus transduction of T cells, the fluorescence intensity of MART-1 in T cells was detected by flow cytometry through the MART-1 tetramer peptide. At the same time, the expression of CD62L on the cell surface and hscIL-12/CD62L and CD107a on the membrane surface were detected by flow cytometry.
- the recombinant lentiviral vector carrying the human TCR ⁇ and ⁇ chain genes which specifically recognize the human melanoma-associated antigen MART-1 was transfected into autologous peripheral blood lymphocytes by molecular biological techniques, and the recombinant TCR was expressed in T lymphocytes.
- a TCR expression vector containing a self-cleaving 2A peptide, furin (Furin) and a spacer sequence was constructed using a lentiviral vector with an optimized promoter.
- CD62L lentiviral expression vector Construction of the CD62L lentiviral expression vector was based on published literature (Yang, Cohen et al. 2008, Yang, Liu et al. 2011), and the construction of hscIL-12 was referenced to published literature (Zhang, Kerkar et al. 2011).
- the fusion protein of hscIL-12/CD62L is linked by the peptide G 6 S and 218 peptides, respectively.
- 293T cells were cultured, and the cell density was adjusted in DMEM medium containing 10% fetal bovine serum one day before transfection. Then, 25 ⁇ 10 6 293T cells were inoculated per 15 cm cell culture dish, and cultured at 37 ° C, 5% CO 2 . The culture in the box can be used for transfection after the cell density is increased to 80% to 90% after 16h to 24h. On the day of transfection, the medium was changed to complete medium without antibiotics (P/S) (DMEM + 10% FBS).
- P/S DMEM + 10% FBS
- the lentiviral backbones of the LVV-MSCV-MART-1 TCR, CD62L, hscIL-12L, and hscIL-12/CD62L fusion proteins were co-transfected into 293T cells together with three other packaging plasmids, using commercially available calcium phosphate as a vehicle. After 6 hours of culture, the medium was discarded, washed 3 times with PBS and replaced with 20 ml of fresh complete medium (DMEM + 10% FBS + P / S). The culture supernatant of 30-72 h after transfection was collected, centrifuged at 6000 rpm for 10 min, and the cell debris was discarded.
- the supernatant was filtered through a 0.45 ⁇ m PVDF filter into a 50 ml round bottom centrifuge tube, centrifuged at 50,000 g for 2 h at 4 ° C, and carefully discarded. Clear, DMEM (free of serum, double antibody) resuspended virus precipitate, according to the amount of virus used each time into a clean 15ml centrifuge tube, stored in a -80 ° C refrigerator, used to infect T cells.
- the titer of the virus detected by the Lentivirus-Associated p24 ELISA Kit was 5 ⁇ 10 7 -1.5 ⁇ 10 8 IFU. For details, see the instructions of the Lentivirus-Associated p24 ELISA Kit. (Yang, Cohen et al. 2008).
- T cells modified by anti-MART-1 TCR gene were co-cultured with 526, 938 cell lines, placed in a 1:1 ratio, ie 1 ⁇ 10 6 per cell, in a 14 ml round bottom polypropylene culture tube, total volume 1 ml, transfer The mixture was incubated in a CO 2 incubator at 37 ° C for 4 h. After 4 h, the cells were centrifuged at 800 x g for 10 minutes, the supernatant was collected, and the cells were lysed by RIPA lysate. The content of IFN ⁇ and IL-12 in the supernatant was detected by an ELISA reagent. IL-12/CD62L on the membrane surface was manipulated by live cell staining of a conventional flow cytometer. CD62L in the supernatant and CD62L in the cells were detected by ELISA kit (R&D Systems, Minneapolis, MN).
- Cell surface CD3, CD8, CD62L, CD107a, IL-12 and CD45RO are detected by fluorescently labeled corresponding antibodies, including isothiocyanate (FITC), allophycocyanin (APC), phycoerythrin (PE), PE-Cy7. , and APC-Cy7 (BD Biosciences, San Jose, CA).
- FITC isothiocyanate
- APC allophycocyanin
- PE phycoerythrin
- PE-Cy7 BD Biosciences, San Jose, CA
- APC-Cy7 BD Biosciences, San Jose, CA.
- the MART-1:27-35 tetramer was designed by the company (iTAg MHC Tetramer, Beckman Coulter, Fullerton, CA) to detect gene-modified TCR expression levels. The specific procedure is as follows.
- the cells were washed twice with FACS staining solution (PBS containing 2% FBS), then 0.2 ml (10 6 /ml) was added to the flow tube, incubated at 4 ° C for 30 minutes, and then washed twice.
- the dead cells were separated by adding 20 ⁇ l PI (l5 ⁇ g/ml propidium iodide) (Sigma-Aldrich, Saint Louis, MO) and cell subpopulation before the sample was taken to achieve the purpose of separation.
- the streaming data is analyzed by FlowJo 8.1.1 for post-processing (FlowJo, Ashland, OR).
- the Pmel experimental mouse model uses conventional methods, for example, see the literature (Overwijk, Tsung et al. 1998).
- the method involved in this experiment was as follows: Female pmel mice (6-8 weeks, 7 mice per group) were selected for intracranial tumor inoculation (IC). B16F10-MART-1 tumor cells were stopped by 0.25% trypsinization with 0.02% EDTA and washed once with serum-containing medium to wash the trypsin reaction, followed by washing twice with PBS. Tumor cells were finally mixed with methylcellulose in zinc option medium in a volume of 1:1, diluted in 5000 cells and loaded into 250- ⁇ l syringe (Hamilton, Reno, NV) in 5 ⁇ l of liquid, using a 25-gauge needle.
- mice received whole body 5 Gy radiation. On day 2, mice received a 0.5-1 ⁇ 10 6 DC vaccine subcutaneously, or a 1 ⁇ 10 7 trans-transfusion of anti-MART-1 TCR and IL-12/CD62L lentiviral gene-modified T cells via tail vein IV.
- Mouse T cells were obtained from mouse spleen cells and activated with 10 ug/ml concanavalin (Con A) in the presence of IL-2 (5 IU/ml); on day 2, the lentiviral vector was shown T cells were transduced, and then cultured for 6 days, cells were collected, and T cells were injected through the tail vein of the mice.
- DC cells of DC group mice were obtained from mouse bone marrow cells, induced differentiation and maturation in vitro for 8 days, and inoculated intraperitoneally. The groups of DCs and T cells are illustrated in the right side of Figure 7. The deaths of the mice were then recorded daily, growth curves were recorded and plotted by Prism mapping software. Asterisks indicate that the experimental group was compared with the other groups, p ⁇ 0.001.
- the fusion gene was synthesized by Invitrogen, and the length and sequence of the fusion gene were confirmed by 1% agarose electrophoresis and sequencing.
- the structure of the obtained fusion gene was constructed as shown in SEQ ID NO.: 1, and the amino acid sequence of the encoded fusion protein is shown in SEQ ID NO.: 2.
- mixture The composition is as follows, take 2ml Optimum I and add pLenti-MSCV (22.5ug), pMD2.G (7.5ug), gag/pol (15ug), pRev (10ug), mix; take 2ml Optimum I and add Lipofectamine 160ul (Invitrogen), mix. The two suspensions were mixed, incubated at room temperature for 5 minutes, and then uniformly added dropwise to the Petri dish.
- the supernatant containing the genetically engineered vector was harvested, centrifuged to remove cell debris at 2000 g, and the supernatant was collected and filtered through a 0.45 uM filter to remove possible contamination, dispensed and stored in a negative 80 refrigerator. According to different needs, the collected virus supernatant can be subjected to ultracentrifugation at 50,000 g to obtain a higher concentration of the viral vector.
- the obtained lentiviral expression vectors were designated as LV-CD62L, LV-hscIL-12/CD62L, LV-hscIL-12, respectively.
- the method is as follows: CD3/CD28 magnetic beads or anti-CD3 antibody activates PBMC, and on day 2, the T cells are modified by lentiviral gene.
- the brief method is as follows: Wash T cells three times in PBS buffer, according to virus titer and T cell A suitable amount of lentivirus was added in a ratio of 3:1, centrifuged at 2000 xg for 2 h, and after 6 h, culture was continued by adding 100 IU/ml IL-2; the second transduction was performed on days 5 to 10, or combined co-transduction. The flask was divided according to the growth of the cells, and two weeks later, the cells modified by the T cells were examined by flow cytometry.
- Anti-tumor TCR can directly produce anti-tumor T cells in vitro by modifying the PBMC of tumor patients with lentiviral genes. This kind of T cells does not require DC induction and has the specific effect of killing tumors.
- T cells cultured for 2-3 weeks in vitro mimics the immune cells produced by the in vivo immune response, and can be divided into CD45RO+/CD62L2 (Tem, effector memory T cells) by flow cytometry.
- CD45RO+/CD62L+ Tcm, central memory T cells
- CD45ROlow/CD62L+ Tn, initial T cells
- the local release of the antigen-reactive tumor immune response of IL-12 can be achieved by genetically modifying anti-tumor T cells to express new IL-12/CD62L molecules and utilizing the characteristics of CD62L tumor antigen reactive cleavage and release. Enhance the local anti-tumor immune response.
- the lentivirus used is a third generation lentiviral vector
- the promoter is MSCV
- the expression gene component can be replaced by a gene to be expressed.
- the 5' and 3' LTR (long terminal repeat) of this vector was transformed into SIN-LTR (self-inactivating-LTR), aiming at reducing the probability of lentiviral recombination, enhancing safety performance, and combining WPRE to terminate RNA transcription. It is currently widely used in clinical carrier structures.
- CD62L and hscIL-12 are linked by a linker peptide.
- T cells were transduced by two transductions, namely MART-1 TCR (first day) and sequential transduction of the three vectors (Day 10). On day 14, the surface of CD cells was detected by flow cytometry. Expression and expression of hscIL-12 on the membrane surface.
- the result is shown in Figure 5.
- the CD62L/IL-12 fusion protein was expressed by the third generation lentiviral vector, and the selected promoter was MSCV, which has been widely used in tumor immunocytotherapy of human body, and has the stability and safety of expression, and the expression of gene components can be
- the gene is replaced by a gene to be expressed, namely, CD62L, MART-1 TCR, and IL-12/CD62L fusion protein.
- the 5' and 3' LTR (long terminal repeat) of the vector were modified into SIN-LTR (self-inactivating-LTR), The aim is to reduce the probability of lentiviral recombination, enhance safety performance, and combine WPRE to terminate RNA transcription. It is the latest generation of genetic engineering vector structure widely used in clinical practice.
- hscIL-12 human single chain IL-12
- CD62L/hscIL-12 hscIL-12 fused IL-12 secreting peptide (lead seq) and linked to lentivirus by gene cloning
- CD62L and hscIL-12 are linked by the peptide SGSG.
- T cells were transduced by two transductions, namely MART-1 TCR (first day) and sequential transduction of the three vectors (Day 10). On day 14, the surface of CD cells was detected by flow cytometry. Expression and expression of hscIL-12 on the membrane surface.
- CD62L can be expressed in a large amount on the surface of anti-tumor T cells.
- IL-12 on the surface of membrane cells can be detected only in the fusion protein group expressing IL-12/CD62L, and the surface of secreted IL-12 membrane is not expressed.
- the mechanism shown in Figure 4 is fully verified.
- the mechanism of the invention is as follows: IL-12 cleaves and releases from the membrane surface by CD62L, and indicates that this release is dependent on the tumor immune response. According to this effect mechanism, the release of biologically active IL-12 can increase the anti-tumor response of anti-tumor T cells, improve the microenvironment of local tumor immunity, and achieve an optimized anti-tumor immune response.
- T cells were sequentially transduced with anti-tumor TCR and CD62L/hscIL-12 fusion protein for 20 days, and co-cultured with tumor cells 526 and 938. After 24 hours, the expression levels of IFN ⁇ and IL-12 in the supernatant were detected by ELISA kit.
- Co-culture of lentiviral vector hscIL-12/CD62L transduced T cells with tumors can enhance the expression level of IFN ⁇ and tumor antigen-dependent release of IL-12.
- T cells were sequentially transduced with anti-tumor TCR and CD62L/hscIL-12 fusion protein for 20 days, and co-cultured with tumor cells 526 and 938. After 24 h, the expression levels of IFN ⁇ and IL-12 in the supernatant were detected by ELISA kit.
- anti-tumor T cells modified by IL-12 soluble gene like the IL-12/CD62L gene modified on the membrane surface, can significantly increase the secretion level of IFN ⁇ compared with the anti-tumor T cell group.
- the present invention further confirmed that only the cleavage and release of IL-12 in the IL-12/CD62L group is associated with activation of tumor antigens, and the sustained secretion of soluble IL-12 is not regulated by tumor antigens and is maintained at a high level. At the same time, the present invention also observes that the level of IL-12 cleavage and release on the surface of the membrane is lower than that of the continuously secreted IL-12, and we predict that the invention has high safety and clinical operability.
- mice Female pmel mice (7 mice per group) were implanted intracranial (IC) by B16F10 cells for 5 days, and mice received 5 Gy whole body radiotherapy 1 day before cell return.
- Mouse T cells were obtained from mouse spleen cells and activated with 10 ug/ml concanavalin (Con A) in the presence of IL-2 (5 IU/ml); on day 2, the lentiviral vector was shown T cells were transduced, and then cultured for 6 days, cells were collected, and (X) 5 ⁇ 10 6 T cells were injected through the tail vein of the mice.
- the DC cells of the DC group were obtained from bone marrow cells, and induced to differentiate and mature for 8 days in vitro, and 1 ⁇ 10 6 cells were inoculated intraperitoneally.
- the groups of DC and T cells are illustrated in the right side of Figure 7. Asterisks indicate that the experimental group was compared with the other groups, p ⁇ 0.001.
- the present inventors have shown that by genetically modifying anti-tumor T cells to express new IL-12/CD62L molecules, and utilizing the characteristics of CD62L tumor antigen reactive cleavage and release, it is possible to achieve a partial immunoreactive tumor immune response of IL-12. Release, enhances the local anti-tumor immune response, and significantly reduces the toxic side effects of IL-12.
- IL-12/CD62L fusion protein gene-modified anti-tumor T cells can not only prolong the survival of tumor-bearing mice, but also avoid the sustained secretion of IL-12.
- Systemic cytotoxicity is a brand new immune cell therapy strategy that expresses IL-12 through cell membrane and cleaves and releases tumor antigen reactivity through CD62L. It will play an important role in the treatment of tumor immune cells. effect.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne une protéine de fusion IL-12/CD62L ainsi que son procédé de préparation et son utilisation. En particulier, la libération de l'IL-12 sur la surface d'une membrane cellulaire activée par l'antigène tumoral est obtenue par une modification des lymphocytes T antitumoraux avec un lentivirus contenant un gène de fusion IL-12/CD62L, ainsi qu'un clivage spécifique et une libération induite par une activation dépendante de l'antigène tumoral CD62L.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510702467.5 | 2015-10-26 | ||
CN201510702467.5A CN105218682B (zh) | 2015-10-26 | 2015-10-26 | 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017071173A1 true WO2017071173A1 (fr) | 2017-05-04 |
Family
ID=54988006
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2016/080420 WO2017071173A1 (fr) | 2015-10-26 | 2016-04-27 | Agent thérapeutique antitumoral modifié par protéine de fusion il-12/cd62l, son procédé de préparation et son utilisation |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN105218682B (fr) |
WO (1) | WO2017071173A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109306340A (zh) * | 2017-07-27 | 2019-02-05 | 上海细胞治疗研究院 | 一种高效扩增全t细胞的人工抗原递呈细胞及其用途 |
CN109337872A (zh) * | 2017-07-27 | 2019-02-15 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
CN110396133A (zh) * | 2018-04-25 | 2019-11-01 | 中国科学院生物物理研究所 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105218682B (zh) * | 2015-10-26 | 2019-05-07 | 杨晶 | 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途 |
CN105585637B (zh) * | 2015-12-23 | 2020-04-03 | 杨晶 | 基于il-12稳定膜表达的肿瘤治疗剂及其制法和用途 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1318644A (zh) * | 2000-04-18 | 2001-10-24 | 西安医科大学 | 一种重组人单链白细胞介素-12的构建方法 |
CN1432064A (zh) * | 2000-03-23 | 2003-07-23 | 格林维尔医院***公司 | 双功能癌症治疗剂 |
WO2003092737A1 (fr) * | 2002-04-30 | 2003-11-13 | Molmed Spa | Fusions de cytokines et de proteines de ciblage tumoral |
CN105218682A (zh) * | 2015-10-26 | 2016-01-06 | 深圳精准医疗科技有限公司 | 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途 |
-
2015
- 2015-10-26 CN CN201510702467.5A patent/CN105218682B/zh active Active
-
2016
- 2016-04-27 WO PCT/CN2016/080420 patent/WO2017071173A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1432064A (zh) * | 2000-03-23 | 2003-07-23 | 格林维尔医院***公司 | 双功能癌症治疗剂 |
CN1318644A (zh) * | 2000-04-18 | 2001-10-24 | 西安医科大学 | 一种重组人单链白细胞介素-12的构建方法 |
WO2003092737A1 (fr) * | 2002-04-30 | 2003-11-13 | Molmed Spa | Fusions de cytokines et de proteines de ciblage tumoral |
CN105218682A (zh) * | 2015-10-26 | 2016-01-06 | 深圳精准医疗科技有限公司 | 经il-12/cd62l融合蛋白改造的肿瘤治疗剂及其制法和用途 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109306340A (zh) * | 2017-07-27 | 2019-02-05 | 上海细胞治疗研究院 | 一种高效扩增全t细胞的人工抗原递呈细胞及其用途 |
CN109337872A (zh) * | 2017-07-27 | 2019-02-15 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
CN109306340B (zh) * | 2017-07-27 | 2023-06-06 | 上海细胞治疗研究院 | 一种高效扩增全t细胞的人工抗原递呈细胞及其用途 |
CN109337872B (zh) * | 2017-07-27 | 2023-06-23 | 上海细胞治疗研究院 | 高效扩增car-t细胞的人工抗原递呈细胞及其用途 |
CN110396133A (zh) * | 2018-04-25 | 2019-11-01 | 中国科学院生物物理研究所 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
CN110396133B (zh) * | 2018-04-25 | 2021-07-23 | 免疫靶向有限公司 | 一种以白介素12为活性成分的融合蛋白型药物前体 |
Also Published As
Publication number | Publication date |
---|---|
CN105218682B (zh) | 2019-05-07 |
CN105218682A (zh) | 2016-01-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108018299B (zh) | 靶向bcma的嵌合抗原受体及其用途 | |
US20210177902A1 (en) | Ror-1 specific chimeric antigen receptors and uses thereof | |
CN109306016B (zh) | 共表达细胞因子il-7的nkg2d-car-t细胞及其用途 | |
CN108728459B (zh) | 靶向cd19的嵌合抗原受体并联合表达il-15的方法和用途 | |
CN108004259B (zh) | 靶向b细胞成熟抗原的嵌合抗原受体及其用途 | |
CN113913379B (zh) | T淋巴细胞及其应用 | |
CN109320615B (zh) | 靶向新型bcma的嵌合抗原受体及其用途 | |
WO2017071173A1 (fr) | Agent thérapeutique antitumoral modifié par protéine de fusion il-12/cd62l, son procédé de préparation et son utilisation | |
MX2014003176A (es) | Celulas t diseñadas mediante arn para el tratamiento de cancer. | |
US11976134B2 (en) | MUC16 specific chimeric antigen receptors and uses thereof | |
CN108441505B (zh) | 一种靶向ror1的嵌合抗原受体及其用途 | |
CN113416260B (zh) | 靶向Claudin18.2的特异性嵌合抗原受体细胞及其制备方法和应用 | |
CN113896801B (zh) | 靶向人Claudin18.2和NKG2DL的嵌合抗原受体细胞及其制备方法和应用 | |
CN111378625A (zh) | 一种cxcl13趋化型car-t细胞的制备和应用 | |
CN110923255A (zh) | 靶向bcma和cd19嵌合抗原受体及其用途 | |
WO2018103734A1 (fr) | Récepteur d'antigène chimère, son utilisation et son procédé de préparation | |
CN108707619B (zh) | 靶向ror1的嵌合抗原受体及其用途 | |
CN111499766B (zh) | 针对慢性淋巴细胞白血病的免疫效应细胞、其制备方法和应用 | |
CN111978412B (zh) | 武装靶向TGF-β的特异性嵌合抗原受体细胞及其制备方法和应用 | |
CN111378046B (zh) | 一种免疫效应细胞转换受体 | |
WO2017117890A1 (fr) | Protéine de fusion il-12/cd107a, son procédé de préparation et utilisation | |
CN108624607A (zh) | 靶向mesothelin的嵌合抗原受体并对其双重修饰的方法和用途 | |
WO2017107353A1 (fr) | Agent de traitement anticancéreux, son procédé de préparation et son utilisation employant il-12 avec une expression de membrane stable | |
CN110139875B (zh) | Col14a1衍生的肿瘤抗原多肽及其应用 | |
CN108165568B (zh) | 一种培养CD19CAR-iNKT细胞方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16858621 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 16858621 Country of ref document: EP Kind code of ref document: A1 |